CHS 006
Alternative Names: CHS-006; JS-006; TAB-006Latest Information Update: 22 Aug 2024
At a glance
- Originator Shanghai Junshi Biosciences
- Developer Coherus BioSciences; Shanghai Junshi Biosciences
- Class Antineoplastics; Immunoglobulins; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants; TIGIT protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Liver cancer; Non-small cell lung cancer; Solid tumours
Most Recent Events
- 09 Aug 2024 Coherus Biosciences terminates a phase-I/II trial in Solid tumours (Monotherapy, Late-stage disease, Second-line therapy or greater, In adults, In the elderly) in USA (IV) due to the strategic reasons and not for safety concerns(NCT05757492)
- 28 May 2024 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in China (IV, Infusion)
- 10 Jan 2024 Coherus BioSciences terminates its collaboration for CHS-006